




TCF7L2 Antibody


CATALOG NUMBER: 25-138




Antibody used in WB on Human Muscle at 0.2-1 ug/ml.



Antibody used in WB on Hum. Fetal Heart.



Antibody used in WB on Hum. Fetal Lung.



Antibody used in WB on Hum. Fetal Liver.

Specifications

SPECIES REACTIVITY:	Human
TESTED APPLICATIONS:	ELISA, WB
APPLICATIONS:	TCF7L2 antibody can be used for detection of TCF7L2 by ELISA at 1:2500. TCF7L2 antibody can be used for detection of TCF7L2 by western blot at 1 ug/mL, and HRP conjugated secondary antibody should be diluted 1:50,000 - 100,000.
USER NOTE:	Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:	1) Cat. No. XBL-10413 - Fetal Skeletal Muscle Tissue Lysate
PREDICTED MOLECULAR WEIGHT:	65 kDa
IMMUNOGEN:	Antibody produced in rabbits immunized with a synthetic peptide corresponding a region of human TCF7L2.
HOST SPECIES:	Rabbit

Properties

PURIFICATION:	Antibody is purified by peptide affinity chromatography method.
PHYSICAL STATE:	Lyophilized
BUFFER:	Antibody is lyophilized in PBS buffer with 2% sucrose. Add 50 uL of distilled water. Final antibody concentration is 1 mg/mL.
CONCENTRATION:	1 mg/ml
STORAGE CONDITIONS:	For short periods of storage (days) store at 4°C. For longer periods of storage, store TCF7L2 antibody at -20°C.

As with any antibody avoid repeat freeze-thaw cycles.

CLONALITY:	Polyclonal
CONJUGATE:	Unconjugated

Additional Info

ALTERNATE NAMES:	TCF7L2, TCF-4, TCF4
ACCESSION NO.:	NP_110383
PROTEIN GI NO.:	170014696
OFFICIAL SYMBOL:	TCF7L2
GENE ID:	6934

Background

BACKGROUND: The TCF7L2 is a high mobility group (HMG) box-containing transcription factor implicated in blood glucose homeostasis. The study of Yi et al. suggested that TCF7L2 acts through regulation of proglucagon through repression of the proglucagon gene in enteroendocrine cells via the Wnt signaling pathway. The TCF7L2 gene product is a high mobility group (HMG) box-containing transcription factor implicated in blood glucose homeostasis. The study of Yi et al. (2005) [PubMed 15525634] suggested that TCF7L2 acts through regulation of proglucagon (MIM 138030) through repression of the proglucagon gene in enteroendocrine cells via the Wnt signaling pathway.

REFERENCES: 1) Ren, Q., (2008) Diabetologia 51 (7), 1146-1152.

FOR RESEARCH USE ONLY

December 12, 2016